
United States · Research startup
A2 Biotherapeutics, Inc.
Funding reportedLast round: Series B
A2 Biotherapeutics, Inc.
is a clinical-stage biotechnology company based in Agoura Hills, California, founded in 2018. The company is focused on developing precision CAR T-cell therapies for solid tumors using its proprietary TmodTM cell engineering platform. This innovative technology enables T cells to selectively target tumor cells while sparing normal cells, addressing a significant challenge in cancer treatment. The company is advancing a pipeline of first-in-class logic-gated cell therapies aimed at treating various solid tumors, including pancreatic, lung, colorectal, ovarian, and mesothelioma cancers. A2 Biotherapeutics operates within the oncology sector, serving cancer patients globally through a business-to-business model that delivers its therapies via healthcare systems and oncology clinics. With a strong foundation in both autologous and allogeneic applications, A2 Biotherapeutics is committed to restoring health and hope for individuals living with cancer and other serious diseases.
Funding, as reported
From A2 Biotherapeutics, Inc.'s own website: 4 on the team.
What they build
Known for
research infrastructurehospital & health careresearchbiological pathwayshealth caretumor microenvironmenttumor immunologycompanion diagnosticoncologycellular immunotherapyresearch and developmenttargeting tumor microenvironmentinnovative therapiesallogeneic cell therapycancer immunologycgmp manufacturing
Built with from their website
YoastYoast SEOGoogle MapsCookieYesKnowBe4123ContactFormAmazon SESWP RocketMicrosoft Email ProvidersCloudFlare CDN
Google Tag Manager123FormBuilderHTTP/3Cloudflare Rocket LoaderGoogle Maps (Non Paid Users)Amazon Simple Email ServiceOWL CarouselBootstrap
Add your raise, your deck and your story, and put A2 Biotherapeutics, Inc. in front of investors. Or tell us what we have wrong.